Menu

IMPORTANT CME CREDIT NOTICE

CME Certificates will be issued digitally after Speaker Evaluations and Overall Surveys are completed. Surveys are accessible after logging in with the email address you submitted during registration. Surveys will be available online starting the day of the symposium. You must complete the process by May 13, 2024 in order to receive your certificate. Certificates will be available online until September 1, 2024 and are printable directly from the website.

ACCREDITATION

The AAFP has reviewed 28th Annual Heart Failure 2024: An Update on Therapy and deemed it acceptable for up to 6.0 Live AAFP Prescribed credits. Term of Approval is from 04/20/2024 to 04/20/2024. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 credit(s)™ toward the AMA Physician's Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.

COURSE DESCRIPTION

The 28th Annual Heart Failure 2024: An Update on Therapy continues the tradition of providing a comprehensive update on the prevention, diagnosis, and management of heart failure. The program includes lectures presented by experts combined with an opportunity for interactive discussion with faculty. The extensive list of topics has been selected to provide a contemporary, high level and clinically relevant update with a goal of improving clinicians’ knowledge and the care of patients with heart failure of various etiologies.

At the conclusion of this activity, participants should be able to:

  1. To review the appropriate use of guidelines directed medical therapy for patients with chronic heart failure with reduced and preserved ejection fraction.
  2. To discuss the management of hospitalized patients with acute decompensated heart failure.
  3. To provide an update on the use of catheter based interventions for the management of patients with heart failure due to valvular heart disease.

TARGET AUDIENCE

The program has been designed to provide cardiologists, internists, primary care physicians, pharmacists, nurses and other healthcare providers with the necessary information to increase knowledge with the goal of improving the care of patients with HF.

NEEDS ASSESSMENT

Current estimates are that nearly 6.5 million Americans over the age of 20 have heart failure (HF) and there are 960,000 new cases annually. HF is one of the most common causes of cardiovascular mortality and severe morbidity. Recently developed and approved drugs and devices for the management of heart failure provide a great opportunity for improved outcome and need to be incorporated into the care of patients with heart failure. Recent data continues to show an important gap between published guideline recommendations for diagnosis and treatment of heart failure and practice (Journal of clinical medicine 2023; 12:1020) and demonstrates that life-saving drugs and devices are underutilized.  Inadequate guideline directed medical therapy (GDMT) has been shown to confer a significant excess mortality (Clin Cardiol. 2021; 44:1192–1198). Most patients with HF are managed by non-cardiologist health care providers and providers without training in advanced heart failure ( Int J Cardiol 2021; 343:63) . Physicians’ education has been shown to result in a significant improvement in knowledge scales in HF care. (PLoS One2022 Feb 4;17(2): e0263523). Non-surgical, catheter-based repair of different valves is available to patients with heart failure who are at high risk for surgery. There is still underutilization of these procedures. (Cardiovasc Revasc Med 2022; 37:712) For all these reasons there is a need for education and incorporation of recent guidelines by clinicians. The 2024 symposium continues the tradition of almost 3 decades and has been designed to provide a comprehensive update on many of the new diagnostic and therapeutic modalities as well as information on new practice guidelines for the management of patients with HF.